Chun Yu Pan
Directeur/Membre du Conseil chez UWELL Biopharma, Inc.
Profil
Chun Yu Pan currently works at UWELL Biopharma, Inc., as Director.
Mr. Pan also formerly worked at Shangya Technology Co., Ltd., as Director-Supervisory Board and Vectorite Biomedical, Inc., as Director from 2011 to 2014.
Mr. Pan received his Masters Business Admin degree from Chinese Culture University.
Postes actifs de Chun Yu Pan
| Sociétés | Poste | Début |
|---|---|---|
UWELL Biopharma, Inc.
 UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | Directeur/Membre du Conseil | - |
Anciens postes connus de Chun Yu Pan
| Sociétés | Poste | Fin |
|---|---|---|
| VECTORITE BIOMEDICAL INC. | Directeur/Membre du Conseil | - |
| SHANGYA TECHNOLOGY CO., LTD. | Directeur/Membre du Conseil | - |
Formation de Chun Yu Pan
| Chinese Culture University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SHANGYA TECHNOLOGY CO., LTD. | Health Technology |
| VECTORITE BIOMEDICAL INC. | Transportation |
| Entreprise privées | 1 |
|---|---|
UWELL Biopharma, Inc.
UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | Health Technology |